key: cord-0767914-ug2neo5o
authors: Gordon, Marcia N.; Heneka, Michael T.; Le Page, Lydia M.; Limberger, Christian; Morgan, David; Tenner, Andrea J.; Terrando, Niccolò; Willette, Auriel A.; Willette, Sara A.
title: Impact of COVID‐19 on the Onset and Progression of Alzheimer's Disease and Related Dementias: A Roadmap for Future Research
date: 2021-12-07
journal: Alzheimers Dement
DOI: 10.1002/alz.12488
sha: 0e135d51882a9a03af98c693486ed03699d2ca9e
doc_id: 767914
cord_uid: ug2neo5o

COVID‐19 causes lasting neurological symptoms in some survivors. Like other infections, COVID‐19 may increase risk of cognitive impairment. This perspective highlights four knowledge gaps about COVID‐19 that need to be filled to avoid this possible health issue. The first is the need to identify the COVID‐19 symptoms, genetic polymorphisms and treatment decisions associated with risk of cognitive impairment. The second is the absence of model systems in which to test hypotheses relating infection to cognition. The third is the need for consortia for studying both existing and new longitudinal cohorts in which to monitor long term consequences of COVID‐19 infection. A final knowledge gap discussed is the impact of the isolation and lack of social services brought about by quarantine/lockdowns on people living with dementia and their caregivers. Research into these areas may lead to interventions that reduce the overall risk of cognitive decline for COVID‐19 survivors.

The A central question that remains is whether the neurological symptoms observed in people with COVID-19 are due to (i) overstimulation of a systemic inflammatory response/cytokine storm, (ii) encephalitis as a result of brain invasion of SARS-CoV-2, or both, (iii) perfusion deficits through vasculitis or vasculopathy, (iv) the induction of autoimmune reactions, or (v) peripheral organ dysfunction ( Figure 1 ). The investigation of disease mechanisms is critical to apply the appropriate treatments in patients with acute or chronic brain alterations, and could be crucial to treat COVID-19 properly to prevent subsequent cognitive decline (Figure 1 ). Thus, it is critical to ascertain whether infection with SARS-CoV2 increases the risk of subsequent, long-term cognitive decline and/or accelerates the onset or progression of AD and AD-related dementias.

Modes of SARS CoV-2 impact on the central nervous system. There are multiple means by which COVID-19 may lead to neural dysfunction. There can be direct brain invasion by SARS-CoV2 during systemic infection. Vascular inflammation and pathological changes of the cerebral vessel endothelium represents a second route by which Covid-19 can affect brain function, together with a systemic coagulopathy this pathological mechanism may account for ischemic strokes. A major concern is the extreme systemic inflammatory reaction which can feedback onto the brain and provoke neural damage through the excess generation of inflammatory mediators including complement factors, prostanoids, cytokines and chemokines. A further mechanism is the generation of self-recognizing antibodies causing autoimmune disease including but not limited to Guillain-Barré syndrome as a consequence of immune recognition of the virus.. Finally, the transient or persistent loss of normal function of peripheral vital organs may have lasting impact on the brain. Further possible consequences of therapy such as unwanted side-effects of antiviral medication or vaccination may have to be considered in future.

We must develop an understanding of short-and long-term cognitive sequelae that contribute to decreased quality of life and cost to society, especially in diverse populations. If even a fraction of COVID-19

infected individuals experience increased risk, there would be a great increase in cognitive decline and/or AD in the future. In this roadmap, we discuss research knowledge gaps and highlight strategies to help mitigate the effects of COVID-19 on the brain, particularly in at-risk populations.

These long-term cognitive consequences may be especially widespread or severe for historically underserved racial and ethnic groups. In Northern California, for example, positivity rates are twice as high in African-Americans and four times higher in Hispanic adults versus Whites 15 . African-Americans communities also have disproportionately higher death rates due to COVID-19 16, 17 . More positive and severe cases may, in turn, lead to greater risk for AD, despite

Hispanic and African-American seniors already being 1.5 and 2 times as likely to develop Alzheimer's disease or other dementias 18 . It is therefore essential to investigate, understand, and treat brain health and cognitive function in this highly at-risk crossover population, to avoid a considerable increase in future patient numbers of AD, which already requires 1 in 5 Medicare dollars 19 .

Based upon clinical presentation, studies should be undertaken to identify individuals who are at increased risk of current or subsequent cognitive decline after SARS-CoV-2 infection. It will be necessary to determine novel syndromes resulting from SARS-CoV-2 infection that predict the risk of subsequent cognitive decline. This will codify, to the extent feasible, those variables in medical records that are most important to collect for the purposes of predicting later cognitive function. To identify those most at risk, three categories of factors should be monitored as detailed below, with clarification of the existing gaps in knowledge to guide future research studies. All three factors will stratify by race, sex and age. 

Biomarkers are needed to: 1) distinguish neurological symptoms in patients with mild or asymptomatic infection; 2) determine if levels of inflammatory and brain injury markers also predict the risk of cognitive decline; 3) provide molecular insights into COVID-19 pathogenesis and progression, and 4) to monitor treatment effects. However, there are substantial barriers to this approach that must be overcome.

Most of the current studies with these biomarkers have been carried out in small populations, which can provide a biased representation.

Larger sample sizes focusing on the neurological and neuropsychiatric alterations of patients are needed to overcome this barrier. This need is compounded by patients with remarkably diverse disease symptoms that reflect severe, mild, or asymptomatic infection 5 . Likewise, it will be important to test sub-populations of individuals with different comorbidities such as metabolic syndrome, cardiovascular, immunosuppressive and chronic respiratory diseases, and substance use disorders 20 as well as the contribution of aging to the risk of neurological damage. More broadly, COVID-19 and AD may share broad neuropathological signatures that offer other routes of discovery for biomarkers. SARS-CoV-2 infection is associated with an exaggerated systemic inflammatory response that can cause blood-brain barrier (BBB) breakdown. In turn, this can exacerbate brain damage by allowing entry of viral particles, peripheral immune cells, and other molecules into the CNS 28 . Therefore, measuring BBB permeability biomarkers might also be useful, such as CSF/plasma albumin ratio 29 , PDGFRβ 30 and perhaps tight junction markers impacted by AD pathology, such as claudin-5 and occludin 31 . Further, it is necessary to identify whether the BBB disruption is a transient or long-term complication, as observed in neurodegenerative diseases. Such disruption may also affect nutrient transport or uptake based on related genotypes. For example, deleterious mutations in water channel genes like aquaporin-4 can impact nutrient transport across the BBB 32 and cognitive decline 33 .

Dysregulated glucose metabolism may also be a common culprit for inducing cognitive disruption in COVID-19 and AD. Obesity causes systemic inflammation and metabolic dysfunction. In turn, excess glucose and insulin are related to COVID-19 severity risk, and insulin treatment worsens outcomes 34 . Similarly, acute or lingering COVID-19 effects may exacerbate the relationships of these obesity factors on cognitive decline 35 , brain atrophy 36 , and reduced brain glucose use in parietal and frontal areas that subserve memory and higher-order cognition 37 .

This last point is key, as less glucose use in these areas is one of the earliest signs of AD. SARS-CoV-2 infection may directly cause the immune cells of the brain to further alter this metabolism. It may therefore be important to use PET imaging to track brain glucose use, beta-amyloid deposition, tau accumulation, immune activation, or even MRI-based blood flow as a reasonable proxy, to establish the neural correlates of COVID-19 cognitive dysfunction.

Besides the analysis of fluid biomarkers, such neuroimaging measurements are fundamental to understand mechanisms that could lead to cognitive decline. Current COVID-19 imaging data is limited to small case series, so larger clinical cohorts are needed to confirm related brain parenchymal signal alterations. When available, brain MRI has been widely used across institutions to evaluate patients with neurological manifestations [38] [39] [40] . PET imaging could separately provide several insights. First, in vivo imaging for markers of neuroinflammation via PET ligands (TSPO, COX-2) may inform clinical evaluation of COVID-19 and preclinical risk of cognitive decline. PET imaging can also track metabolic and neurotransmission signaling system changes that accompany neurological damage and cognitive decline. Finally, PET has determined pathophysiological mechanisms underlying neurodegenerative disease and cognitive decline (e.g., amyloid beta, tau) that may also be relevant for COVID-19 41 . However, acquiring imaging data of COVID-19 patients might be challenging depending upon the setting. The spread of SARS-CoV-2 in some centers could be enhanced due to the entry of infected patients into imaging facilities. In addition, the protocol to perform brain imaging in unstable patients under intensive care may not be possible in all cases. One strategy could be to take neuroimaging measures after total recovery from COVID-19 and correlate it with cognitive tests and fluid biomarkers in a follow-up. Consequently, historical averaged data of patients would be available for comparative purposes. The obtained imaging data could help to determine whether the CNS impact is transient or long-lasting, and detail the cells and brain regions affected.

Several studies have identified genetic risk factors associated with severity and/or susceptibility to infection with COVID-19, which may be important contributors to cognitive dysfunction. For example, it is well known that blood type O is slightly protective and type A carries slightly greater risk 42 

To enable controlled mechanistic studies and therapeutic interven- In the USA, there are the NIA ADRC cohorts which are followed longitudinally, have a core set of cognitive function evaluations and in many cases brain imaging, in addition to a series of ongoing observational and interventional cohorts including large numbers of older adults.

Most older adults enrolled in these longitudinal cohorts have relatively in-depth cognitive evaluations that are repeated at set intervals. Within these cohorts, COVID-19 patients and survivors could be identified. This design offers the opportunity to examine the rates of cognitive decline among these groups, as opposed to cross-sectional measurement of mean cognition scores for those with exposure compared to those without exposure outside of longitudinal studies. One approach to consider is to establish case controls for the index participants. Within the same study cohort, an individual confirmed to have been exposed to COVID-19 would be matched for age, sex, APOE status, cognitive performance and possibly other variables to another study participant who has not been exposed to COVID-19. There may be an opportunity to confirm non-exposure with antibody testing for The Long-COVID patient population ('COVID long-haulers') must also be closely monitored specifically for cognitive decline. Repeated monitoring/measuring of early biomarkers of decline will enable prevention of years of costly treatment. Research is needed to define in detail the impact of these long-term symptoms on the brain in this at-risk patient population. Large scale studies of invasive and non-invasive measures of brain health must be carried out as soon as possible to be able to document any COVID-relevant changes, and to enable patients to recall pre-COVID experiences/health more accurately.

Another potential role of longitudinal cohorts may be to identify social factors influencing risk. Irrespective of exposure, the pandemic has considerable impact on the psychological well-being of many older adults (as well as young people). We expect there will be long term con- Given the vast numbers of Americans who will be vaccinated over the next few months, ranging in age, race, and socioeconomic status, there is a unique opportunity to reach many people who may not otherwise have contact with healthcare providers.

First, this could either be used to collect information on a population to follow in the future in the types of longitudinal studies described can be relevant. Components of an educational program should include education on brain health, awareness of symptoms and societal preparation for significant uptick in future patients with cognitive decline, potentially from a younger age.

We suggest an immediate implementation of strategies that will enable us to foresee a virus-induced "new wave" of dementia. This will allow both for planning for new cases and for development of novel effective therapeutics applied either at the initial onset of infection or later to prevent the development of neurological damage and subsequent loss of cognitive ability. The proposed organization of primary research could additionally be a relevant guide for future pandemics involving neurological effects from infection, laying out a framework for rapid response. We do not claim that these four areas are exhaustive of the knowledge needed to prepare for the cognitive consequences of the current and future pandemics. However, we wish to highlight these priorities, and the need to move quickly before data and samples are lost. 

The chronic neuropsychiatric sequelae of COVID-19: The need for a prospective study of viral impact on brain functioning

Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19

Neurologic Features in Severe SARS-CoV-2 Infection

Neurological infection with SARS-CoV-2 -the story so far

Effects of COVID-19 on the Nervous System

Could COVID-19 anosmia and olfactory dysfunction trigger an increased risk of future dementia in patients with ApoE4? Med Hypotheses

Protein Expression of Angiotensin-Converting Enzyme 2 (ACE2) is Upregulated in Brains with Alzheimer's Disease

Long-term cognitive impairment and functional disability among survivors of severe sepsis

Persistent cognitive impairment, hippocampal atrophy and EEG changes in sepsis survivors

Delirium in Older Patients With COVID-19 Presenting to the Emergency Department

Delirium accelerates cognitive decline in Alzheimer disease

Association of Delirium With Cognitive Decline in Late Life: A Neuropathologic Study of 3 Population-Based Cohort Studies

Delirium is a strong risk factor for dementia in the oldest-old: a population-based cohort study

The Impact of COVID-19 Disease on Platelets and Coagulation

Racial Disparities in COVID-19 Testing and Outcomes : Retrospective Cohort Study in an Integrated Health System

COVID-19 exacerbating inequalities in the US

Analyses of Risk, Racial Disparity, and Outcomes Among US Patients With Cancer and COVID-19 Infection

Alzheimer's disease facts and figures

COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States

Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19

Biomarkers for central nervous system injury in cerebrospinal fluid are elevated in COVID-19 and associated with neurological symptoms and disease severity

Proteomic and Metabolomic Characterization of COVID-19

Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)

Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis

Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients

Predictors of hippocampal atrophy in critically ill patients

Structure and function of the blood-brain barrier

CSF and blood biomarkers for the diagnosis of Alzheimer's disease: A systematic review and metaanalysis

Shedding of soluble platelet-derived growth factor receptor-β from human brain pericytes

Selective loss of cortical endothelial tight junction proteins during Alzheimer's disease progression

Genetic variation in Aquaporin-4 moderates the relationship between sleep and brain Abeta-amyloid burden

The effects of noncoding aquaporin-4 single-nucleotide polymorphisms on cognition and functional progression of Alzheimer's disease

Insulin Treatment Is Associated with Increased Mortality in Patients with COVID-19 and Type 2 Diabetes

Aging-related changes in fluid intelligence, muscle and adipose mass, and sex-specific immunologic mediation: A longitudinal UK Biobank study

Insulin resistance, brain atrophy, and cognitive performance in late middle-aged adults

Association of Insulin Resistance With Cerebral Glucose Uptake in Late Middle-Aged Adults at Risk for Alzheimer Disease

Brain MRI Findings in Severe COVID-19: A Retrospective Observational Study

Brain MRI Findings in Patients in the Intensive Care Unit with COVID-19 Infection

Early postmortem brain MRI findings in COVID-19 non-survivors

PET Imaging as a Tool for Assessing COVID-19 Brain Changes

Testing the association between blood type and COVID-19 infection, intubation, and death. medRxiv

Genomewide Association Study of Severe Covid-19 with Respiratory Failure

A genomic region associated with protection against severe COVID-19 is inherited from Neandertals

Biological Factors Linking ApoE epsilon4 Variant and Severe COVID-19

Animal models for COVID-19

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Neuroinvasion of SARS-CoV-2 in human and mouse brain

Model organism development and evaluation for late-onset Alzheimer's disease: MODEL-AD

SARS-CoV-2 Infectivity and Neurological Targets in the Brain

Updated experimental estimates of the prevalence of long COVID symptoms

6-month consequences of COVID-19 in patients discharged from hospital: a cohort study

Dementia prevention, intervention, and care: 2020 report of the Lancet Commission

Impact of COVID-19 on the Onset and Progression of

Alzheimer's Disease and Related Dementias: A Roadmap for Future Research